A. Iqbal1, A. Yasinzai2, D. Bernal-Olaveria3, K. Ballur4, A. Wali2, S. Ballur5, M. Khan6, I. Khan7, L. Tijani3, A. Ullah3 1Northeastern Health System, Tahlequah, Medicine, Tahlequah, OK, USA 2Bolan Medical College Quetta, Medicine, Quetta, BALUCHISTAN, Pakistan 3Texas Tech University Health Sciences Center, Lubbock, TX, USA 4Medical College Of Georgia, Radiology, Augusta, GA, USA 5University of Georgia, Athens, GA, USA 6Marshfield Clinic, Medicine, Marshfield, WISCONSON, USA 7Insight Medical Center, Medicine, Chicago, IL, USA
Introduction:
Pancreatic acinar cell carcinoma (PACC) is a rare cancer involving acinar cells from the pancreas. This study aims to elucidate and compile existing data regarding PACC and expand on the existing literature.
Methods:
Data from 488 patients diagnosed with PACC from the Surveillance, Epidemiology, and End Results (SEER) database was extracted. Data was analyzed for demographics, tumor characteristics, treatment modalities, and survival rate. The log-rank test was used to compare survival functions. Multivariate analysis using Cox survival regression was used to identify factors associated with increased mortality.
Results:
The median age was 64.7 years, the most common race was the White population (83.6%), and the most common gender was Male (70.5%). Regarding tumor grading “poorly differentiated carcinoma” was the most common subtype (45.8%). The distant stage was the most common, in known cases of tumor stage (50.1%). The metastasis status was known in 284 (58.2%) cases; of this group, 117 presented metastatic lesions; liver was the most common metastasis site (31.3%). Only chemotherapy modality offers better survival in the short term (<24 months). The overall 1-year and 5-year survival rates were 53.2% (95% CI, 47.9-58.2) and 19.2% (95% CI, 14.9-23.8), respectively. The cause-specific 1-year and 5-year survival rates were 55.0% (95% CI, 49.6-60.1) and 22.4% (95% CI, 17.7-27.5), respectively. Patients treated with multimodal therapy (surgery with chemoradiation) over surgery or chemotherapy alone had better. 1-year and 5-year survivals of 91.7% (95% CI, 70.6-97.8) and 53.5% (95% CI, 31.8-71.0) respectively. Multivariable analysis identified age >60 and distant stage as factors associated with increased mortality.
Conclusion:
This study brings comprehensive insights regarding demographic, therapeutic, and prognostic factors, adding evidence to the current knowledge. This retrospective population-based study creates opportunities to improve the quality of healthcare assistance for uncommon conditions. It points out the need for discoveries regarding screening, mutation analysis, and personalized treatments.